Avalanche Int’l Shares Clinical Study Using Avatar Vape Pen and e-Liquids

50% of Participants Quit Smoking, 92% Reduce Cigarette Use, CO Blood Level Lowered As Much As 10XLAS VEGAS, NV, Nov 24, 2014 (Marketwired via COMTEX) Avalanche International, Corp. (OTCQB: AVLP) announced today in conjunction with its wholly-owned subsidiary, Smith and Ramsay Brands, LLC (SRB), that a clinical study was released Saturday, November 15, 2014 by the Italian Observatory for Smoking, Alcohol and Drug Use at the Institute of Health (ISS) in collaboration with the San Giovanni Bosco Hospital Smoking Center ASL TO2 of Turin. The 4-month study chose 34 volunteers, 18 men and 16 women, with histories of smoking 20 cigarettes or more a day for at least 20 years and a mean age of 40. The experiment measured many factors including the amount of carbon monoxide in the breath and blood to demonstrate the degree of toxins absorbed in the body. The study used only the Avatar vape pen and e-Liquids along with proprietary replacement components supplied by Smart Evolution Trading, srl (
http://bit.ly/1r2iykb